Why this Houston entrepreneur stuck with startups over a corporate gig

Guest column

When Microsoft came knocking on this Houston entrepreneur's door, he realized leaving the startup world was not something he was willing to do. Pexels

Several ago, Microsoft dangled a senior leadership role in front of me, which included a high-compensation offer and the chance to move to Seattle. It was tempting. On the surface, this might seem like an easy choice. This kind of senior management position at Microsoft is something many people only dream of. And Microsoft was making a hard push for me.

Then, while pondering the offer, I imagined how I would change the company's website to capitalize on an urgent market opportunity, and then I thought about the bureaucracy I'd have to go through, which I imagined would have been like trying to get a bill through Congress. I called the hiring manager and asked for an example of his team advocating for such a change, and he confirmed that it would require jumping in slow motion through layers of hoops.

I couldn't get myself to leave the high-flying startup atmosphere where I had the freedom to move the needle in quantum leaps, not increments. It's a big decision to choose to share your talents with a startup versus a large corporation. Both options include benefits and risks. But if you have an entrepreneurial mind-set, you will discover, like I did, that startups can offer huge benefits. Here are what I see as the top four.

1. Fewery barriers of entry

While big corporations often choose to hire the candidates who went to Ivy League schools, are well-connected, or have loads of experience at higher-level positions, startups are interested in something else. They choose to hire people who think creatively, show a willingness to work hard, and demonstrate raw leadership qualities that, once cultivated, can help the company (and the individual) achieve breakthrough success. Startup entrepreneurs are creators, not maintenance workers, and startups need visionaries at every level.

2. Versatility in roles

Most jobs in big companies offer a limited range of authority, meaning no single individual, besides perhaps the CEO, has the ability to influence the entire company in a significant way. When you get hired to fill a role at an established business, that's exactly what they expect you to do: fill that role.

It's rare, if not impossible, to find the freedom to experiment and try your hand at filling different roles within various departments. Most startups don't hire with a set idea of your potential or career path, because the startup is young and undergoing massive change.

Founders may find it hard to predict what the company's needs will be as it grows. This is the perfect environment to try on different hats and find your zone of genius — the area where you work best — then move up quickly from there.

3. Financial rewards

Go to work for a big company, and you'll get a paycheck — a paycheck and a 4 percent annual raise along with a formal review from a manager who dreads delivering it. The potential upside is far greater at startups. And the initial financial rewards might not be too bad either.

Depending on the size and cash flow, a startup may offer a competitive salary right off the bat, or it may start you off with a modest salary with the potential to own a piece of the pie through stock options. The stock options could lead to astronomical compensation later on, if the company is successful. In my opinion, always go for the stock options.

4. Upward mobility

If you have enough drive, it is possible to climb the old guard corporate ladder but be prepared for a slow climb. Incumbent companies are burdened with incumbent mind-sets. Barriers to advancement are high, and opportunities are few. If you have set your sights on making it to the C-suite of a Fortune 500 company, your opportunities are severely limited. Among those companies, there can only be 500 CEO positions, maybe 5,000 in the rest of the C-suite. That means your odds of getting a job in the C-suite of a Fortune 500 company are lower than the odds of being drafted by the National Football League — way lower considering the NFL drafts 224 new players each year,and people tend to linger in the C-suite quite a bit longer than that.

Compare these numbers to the 46,500 startups in the United States, and it's easy to see there are far more executive leadership opportunities at startup companies. If you believe your corporate destiny is to become a leader, you can find a startup with a dynamic, fast-moving environment that values initiative and offers the opportunity to move up quickly.

------

Steven Mark Kahan has successfully helped to grow six startup companies from early-stage development to going public or being sold, resulting in more than $3 billion in shareholder value. He is also the author of a the book Be a Startup Superstar. 

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings